Active Stocks: Raptor Pharmaceutical (NASDAQ:RPTP), Pfizer (NYSE:PFE), Merck & Co., (NYSE:MRK), Provectus Biopharmaceuticals (NYSEMKT: PVCT), Pacira Pharmaceuticals (NASDAQ:PCRX)

On 15 JUNE Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $11.81 million. The company’s quarterly revenue was up on a year-over-year basis. Analysts expect that Raptor Pharmaceutical Corp. will post $-0.74 EPS for the current fiscal year. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) weekly performance is 7.31%. On last trading day company shares ended up $12.04. Analysts mean target price for the company is $20.80. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) distance from 50-day simple moving average (SMA50) is 37.41%.

On 20 JUNE Pfizer Inc. (NYSE:PFE) and Cellectis announced that the two entered into global strategic collaboration for development of Chimeric Antigen Receptor T-cell (CAR-T) immune-therapies in Oncology field. Chimeric Antigen Receptor T-cell shall be directed at the select targets only. CAR-T platform technology of Cellectis offers an allogeneic and proprietary approach for development of CAR-T therapies, which remain different from various other autologous approaches. Pfizer Inc. (NYSE:PFE) shares advanced 0.64% in last trading session and ended the day on $29.78. PFE Gross Margin is 81.90% and its return on assets is 23.50%. Pfizer Inc. (NYSE:PFE) quarterly performance is -6.65%.

On 20 JUNE Merck & Co., Inc. (NYSE:MRK) announced that it is commencing, through a unit, a cash tender offer to buy all outstanding common shares of Idenix Pharmaceuticals, Inc. (IDIX). After the purchase of shares in the tender offer, Idenix will become a wholly-owned unit of Merck. Merck & Co., Inc. (NYSE:MRK) shares moved up 1.06% in last trading session and was closed at $58.92, while trading in range of $58.44 – $59.28. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 19.54%.

On 6 JUNE Provectus Biopharmaceuticals Inc (NYSEMKT: PVCT) has announced that the data on its PV-10 used in the treatment of solid tumors. Provectus Biopharmaceuticals Inc (NYSEMKT: PVCT) ended the last trading day at $1.01. Company weekly volatility is calculated as 12.32% and price to cash ratio as 11.14. Provectus Biopharmaceuticals Inc (NYSEMKT: PVCT) showed a negative weekly performance of -21.71%.

On 17 JUNE Pacira Pharmaceuticals Inc (NASDAQ:PCRX) reported ($0.19) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s revenue was up 216.4% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $-0.57 earnings per share for the current fiscal year. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) net profit margin is -68.30% and weekly performance is 7.35%. On last trading day company shares ended up $88.12. Analysts mean target price for the company is $91.43. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) distance from 50-day simple moving average (SMA50) is 16.88%.